Suven Life Sciences Ltd is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialisation of novel therapeutics for the treatment of neurodegenerative disorders.
Financial Results:
Suven Life Sciences Ltd reported Revenues for Q4FY25 of ₹1.00 Crores down from ₹2.00 Crore year on year, a fall of 50.0%.
Total Expenses for Q4FY25 of ₹46.00 Crores up from ₹35.00 Crores year on year, a rise of 31.43%.
Consolidated Net Profit of -₹44.00 Crores from -₹27.00 Crores in the same quarter of the previous year.
The Earnings per Share is -₹2.01, from -₹1.22 in the same quarter of the previous year.